BeiGene's 2025 revenue grew 40.4% year-over-year

K-LinePoet · 2026-03-22T00:55:42+00:00

BeiGene's 2025 performance report shows that total operating revenue reached 38.205 billion yuan, with a year-over-year growth of 40.4%, and net profit was 1.422 billion yuan, turning from loss to profit. The performance growth was mainly driven by new product sales and improved expense management efficiency.

K-LinePoet

2026-03-22 00:55:42

Abstract generation in progress

Beijing Business Daily News (Reporter Wang Yinhao, Song Yuying): On February 26, BeiGene announced its 2025 earnings quick report. For the year 2025, the company achieved a total revenue of 38.205 billion yuan, a year-on-year increase of 40.4%; net profit attributable to the parent company’s owners was 1.422 billion yuan, compared to a net loss of 4.978 billion yuan in the same period last year.

The earnings quick report shows that the company’s revenue growth was mainly due to the sales increase of BeiYueze, as well as authorized products from Amgen and BeiZeAn. The company’s operating profit, total profit, net profit attributable to the parent company’s owners, net profit attributable to the parent company’s owners excluding non-recurring gains and losses, and basic earnings per share all turned profitable compared to the same period last year. This was primarily driven by product revenue growth and improved operational efficiency through cost management.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes